Literature DB >> 30366604

Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.

John F Tierney1, Sitaram V Chivukula1, Xuanji Wang1, Sam G Pappas1, Erik Schadde1, Martin Hertl1, Jennifer Poirier1, Xavier M Keutgen2.   

Abstract

BACKGROUND: Patients with gastroenteropancreatic neuroendocrine tumors often present with stage IV disease. Primary tumor resection in these patients remains controversial. Herein, we studied the impact of primary tumor removal, identified variables associated with prolonged survival for each neuroendocrine tumor subtype, and determined factors that influence surgeons to perform primary tumor resection.
METHODS: Patients with metastatic gastroenteropancreatic neuroendocrine tumors diagnosed from 2004 to 2014 were identified from the National Cancer Database. Nested Cox proportional hazards and logistic regression models were used to assess variables associated with survival and primary resection.
RESULTS: A total of 14,510 patients met inclusion criteria. On multivariable analysis, resection of the primary tumor and grade 1 or 2 tumors was associated with prolonged survival in all subtypes (P < .001). Organ-specific variables associated with prolonged survival in patients undergoing primary tumor resection included the following: low grade for all organs; young age for pancreatic, small intestinal, colonic, and rectal neuroendocrine tumor; tumor size for colonic and rectal neuroendocrine tumor; and tumor location for colonic neuroendocrine tumor. Low tumor grade was found to be significantly associated with removal of the primary tumor across all organs.
CONCLUSION: This study is the first suggesting that primary tumor resection is associated with prolonged survival for all gastro-entero-pancreatic NETs. Additional variables related to survival for each NET subtype were identified and might help select patients who benefit from primary tumor removal.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Neuroendocrine tumors; carcinoid tumors; colorectal neoplasms; gastrointestinal neoplasms; pancreatic neoplasms

Mesh:

Year:  2018        PMID: 30366604     DOI: 10.1016/j.surg.2018.09.006

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  17 in total

1.  Resection of Primary Gastrointestinal Neuroendocrine Tumor Among Patients with Non-Resected Metastases Is Associated with Improved Survival: A SEER-Medicare Analysis.

Authors:  Diamantis I Tsilimigras; J Madison Hyer; Anghela Z Paredes; Aslam Ejaz; Jordan M Cloyd; Joal D Beane; Mary Dillhoff; Allan Tsung; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2021-01-05       Impact factor: 3.452

2.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

3.  Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; James R Howe
Journal:  Curr Probl Surg       Date:  2020-05-15       Impact factor: 1.909

Review 4.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

5.  Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: An NCDB Analysis.

Authors:  Sarah R Kaslow; Gerardo A Vitiello; Katherine Prendergast; Leena Hani; Steven M Cohen; Christopher Wolfgang; Russell S Berman; Ann Y Lee; Camilo Correa-Gallego
Journal:  Ann Surg Oncol       Date:  2022-03-05       Impact factor: 5.344

Review 6.  Small bowel neuroendocrine neoplasm: what surgeons want to know.

Authors:  Akshya Gupta; Meghan G Lubner; Jason B Liu; Elizabeth S Richards; Perry J Pickhardt
Journal:  Abdom Radiol (NY)       Date:  2022-03-21

Review 7.  [Surgery of pancreatic neuroendocrine neoplasms: state of the art].

Authors:  A Nießen; S Schimmack; F Billmann; T Hackert
Journal:  Chirurgie (Heidelb)       Date:  2022-05-02

Review 8.  The Landmark Series: Management of Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; James R Howe
Journal:  Ann Surg Oncol       Date:  2021-01-15       Impact factor: 5.344

9.  Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.

Authors:  Mengzhen Zheng; Yan Li; Tong Li; Lianfeng Zhang; Lin Zhou
Journal:  Cancer Med       Date:  2019-07-22       Impact factor: 4.452

Review 10.  Management of Gastrointestinal Neuroendocrine Tumors.

Authors:  Rongzhi Wang; Rui Zheng-Pywell; H Alexander Chen; James A Bibb; Herbert Chen; J Bart Rose
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2019-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.